Dr. Kevin J. Blinder, MD

Dr. Blinder practices at The Retina Institute in Saint Louis, Missouri.

Dr. Blinder's NPI, 1669476560, was assigned on June 8, 2005. Dr. Blinder graduated from University of Missouri, Kansas City, School of Medicine in 1985. Dr. Blinder holds Missouri license R8F59.

Dr. Blinder's primary practice is The Retina Institute, at 12106 Tesson Ferry Rd, Saint Louis, MO 63128 in Saint Louis County. The practice phone is (314) 367-1181.

Dr. Blinder's primary practice is The Retina Institute in Saint Louis, Missouri. Dr. Blinder is also affiliated with Barnes-Jewish Hospital. Dmand AI also links Dr. Blinder to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Blinder practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Blinder's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Blinder is licensed in Missouri.

CMS data shows 38,942 Medicare services from Dr. Blinder across 27 procedure codes in 2024, for 2,047 Medicare patients. Medicare paid $3,315,404 for them.

CMS counts 2,047 Medicare patients who saw Dr. Blinder in 2024. The largest group is 65 to 74, with 767 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Blinder's median patient age at 73, with 55% women.

In 2024, Dr. Blinder wrote 2,691 Medicare Part D claims for 649 patients. 73% of them were for generic drugs. CMS names the drug for 2,619 of them, across 18 drugs with 11 or more claims each, at $98,128 in total drug cost. In 2023, CMS named 2,361 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Blinder for performance year 2024, reported as part of a group. Dr. Blinder accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 41 papers to Dr. Blinder, published from 2010 to 2025. 2020 was the busiest year, with 9. The most frequent topics are Visual Acuity, Tomography, Optical Coherence and Vitrectomy. Dr. Blinder has published most often in Ophthalmol Retina. Dr. Blinder's most frequent co-authors are Gaurav K. Shah, MD, Sabin Dang, MD and Dean Eliott, MD.

Dmand AI links Dr. Blinder to 1 clinical trial. Conditions studied include Vitreous Detachment and Retinal Vein Occlusion. Open Payments lists research payments to Dr. Blinder that name 1 trial.

CMS Open Payments shows 526 general payments to Dr. Blinder from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $186,873. It also lists 8 research payments totaling $991 in 2025, naming 1 clinical trial.

Dr. Blinder graduated from University of Missouri, Kansas City, School of Medicine in 1985.